

Corresponding author(s):

Double-blind peer review submissions: write DBPR and your manuscript number here instead of author names.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main

C+a+ia+iaa	l parameters
STATISTICA	inarameiers

text	, 01	Methods section).
n/a	Со	nfirmed
	\boxtimes	The $\underline{\text{exact sample size}}(n)$ for each experimental group/condition, given as a discrete number and unit of measurement
		An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X		A description of all covariates tested
X		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	\boxtimes	A full description of the statistics including <u>central tendency</u> (e.g. means) or other basic estimates (e.g. regression coefficient) AND <u>variation</u> (e.g. standard deviation) or associated <u>estimates of uncertainty</u> (e.g. confidence intervals)
		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Clearly defined error bars State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on <u>statistics for biologists</u> may be useful.

Software and code

Policy information about availability of computer code

Data collection Gen5 v2.07 (BioTek) used for

Gen5 v2.07 (BioTek) used for data collection on Synergy plate reader, NIS-Elements Basic Research v3.2 (Nikon) used to capture immunofluorescence images, Image Lab v3.2.1 (Bio-Rad) used to capture Immunoblots, HiSeq Control Software (Illumina) for sequencing on HiSeq platform.

on Hised platforf

Data analysis

CLC Genomics 10 (Qiagen) was used to trim and demultiplex NGS data, MAGeCK software v0.5.7 was used for analysis of the sgRNA sequencing data, Prism 7.0 (GraphPad) was used for plotting graphs and for statistical analysis.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All relevant data are available from the corresponding authors upon request.

					• •	•				
ш,	\cap		l cr	$\mathbf{a} \mathbf{c} \mathbf{c}$	\sim ı \pm		ro	$n \cap$	rtir	\mathcal{T}
		I U	1-51	760	III	н.		しハし		12
•	_	_	. –		•	. •	. –	\sim		. 🔾

Please select the best fit for	you	ir research. If you are not sure,	read t	he appropriate sections before making your selection.
∑ Life sciences		Behavioural & social sciences		Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/authors/policies/ReportingSummary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size Sample sizes were based on standards in the field, typically 3 independent biological replicates, with each replicate assayed in technical duplicate or triplicate.

Data exclusions No data were excluded from the analysis.

Replication Yes, for example, GNPTAB was a hit in the CRISPR screen for genes important for Ebola infection - this was then validated as infection was impaired in GNPTAB-knockout HAP1 cells, but was restored upon reconstitution of GNPTAB expression.

Randomization Fibroblasts from patient families were studied together, i.e. fibroblasts from father, mother and proband (along with healthy control and NP-C patient cells) were tested back-to-back.

Blinding not relevant to this study.

Reporting for specific materials, systems and methods

Materials & experimental systems

n/a	Involved in the study				
	☐ Unique biological materials				
	Antibodies				
	Eukaryotic cell lines				
\boxtimes	Palaeontology				
\boxtimes	Animals and other organisms				

Me ⁻	tho	ds		

n/a Involved in the study

ChIP-seq

Flow cytometry

MRI-based neuroimaging

Unique biological materials

Human research participants

Policy information about availability of materials

Obtaining unique materials Patient fibroblasts

Patient fibroblasts are available from the Coriell Institute, HAP1 knockout cells are available from Horizon Genomics.

Antibodies

Antibodies used

Anti-GNPTAB (#PA5-69636, ThermoFisher), anti-myc (clone 9E10, #MA1-980, ThermoFisher), anti-NPC1 (#108921, Abcam), anti-actin (clone AC-15, #A5441, Sigma-Aldrich), anti-CatB (#31718, Cell Signaling Technology) and anti-CatL (#AF952, R&D Systems).

Validation

Anti-GNPTAB and anti-myc, detect bands of expected size upon GNPTAB-myc expression in knockout cells, but not with a control

construct (Fig. 2). Anti-NPC1, lack of detection of a band of expected size in knockout cells (Fig. 2 and manufacturer's website). Anti-CatB, absence of band correlates with lack of activity in biochemical peptide cleavage assay (Fig. 5).

Eukaryotic cell lines

Policy	information	ahout	cell	lines
I UIICV	IIIIOIIIIauoii	about	CEII	IIIICS

Cell line source(s) Fibroblast cell lines were from Coriell Institute. Huh7 cells were from Apath, LLC. Huh7.5.1 cells were from Francis Chisari. A549 and Vero E6 cells were from the CDC core facility.

Authentication None of the cell lines were formally authenticated in our laboratory.

Mycoplasma contamination All cell lines were negative for mycoplasma.

Commonly misidentified lines (See <u>ICLAC</u> register)

No commonly misidentified cell lines were used in this study.